Delving into the Latest Updates on Glutathione with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Glutathione (JP17), Glutathione (reduced type), Tathion

+ [1]

Target-

Action-

Mechanism-

Therapeutic Areas

Infectious DiseasesCardiovascular DiseasesDigestive System Disorders+ [6]

Active Indication

Drug intoxicationHeavy Metal PoisoningHypertension, Pregnancy-Induced+ [9]

Inactive Indication-

Originator Organization

Choseido Pharmaceutical Co., Ltd.

Active Organization

Choseido Pharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

Japan (30 Jun 1967),

ChorioretinitisCorneal UlcerHyperpigmentation+ [3]

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC10H17N3O6S

InChIKeyRWSXRVCMGQZWBV-WDSKDSINSA-N

CAS Registry70-18-8

Prevent CSA-AKI (Cardiac Surgery Associated Acute Kidney Injury) trial is a double blinded randomized controlled trial, 242 patients undergoing elective cardiopulmonary bypass surgery (CPB)will either receive a placebo or daily 1200 mg of Co enzyme Q10 (CoQ10) and 1000 mg of Glutathione (GSH), the first dose will be given the day before surgery and continues while admitted up to 1 week. Blood and urine samples will be collected. Adverse events related to the study drugs will be collected.

Start Date18 Jul 2024

Sponsor / Collaborator

George Washington University

CTRI/2024/04/066261

/ Not yet recruitingPhase 1IIT

COMPARISON OF NANO SILVER FLUORIDE AND SDF WITH GLUTATHIONE TO EVALUATE CARIOSTATIC POTENTIAL AND DISCOLORATION IN PRIMARY TEETH-A RANDOMIZED CONTROL TRIAL - NIL

Start Date20 May 2024

Sponsor / Collaborator-

100 Clinical Results associated with Glutathione

Login to view more data

100 Translational Medicine associated with Glutathione

Login to view more data

100 Patents (Medical) associated with Glutathione

Login to view more data

147,935

Literatures (Medical) associated with Glutathione

01 Dec 2025·Molecular Genetics and Genomics

Methyltransferase-like 14 promotes ferroptosis in sepsis-induced acute kidney injury via increasing the m6A methylation modification of LPCAT3

Article

Author: Wang, Qi-Juan ; Xu, Lei ; Chen, Ze-Fu ; Nie, Ming-Xi

Acute kidney injury (AKI) is one of the most serious and common complications in the course of sepsis, known for its poor prognosis and high mortality rate. Recently, ferroptosis, as a newly discovered regulatory cell death, might be closely associated with the progression of AKI. METTL14 is a writer of RNA m6A, an abundant epigenetic modification in transcriptome with broad function. Hence, the purpose of our study is to explore the potential function and mechanism of METTL14 on the ferroptosis in sepsis-induced AKI. In this paper, TCMK-1 cells and mice treated with LPS were used to constructe AKI model in vitro and in vivo. Pathological changes of renal tissue were observed by HE staining. The fluorescent probe C11-BODIPY and 4HNE kits were used to measure the lipid peroxidation. The ferroptosis index was evaluated by MDA, GSH and Fe²⁺ kits. The total m6A levels were analyzed by EpiQuik M6A RNA methylation kit, and the m6A levels of LPCAT3 were examined by Me-RIP assay. Finally, the interaction between LPCAT3 and METTL14 was clarified using RIP and dual-luciferase reporter gene assays. Our works revealed that the m6A level and ferroptosis was markedly ascended in LPS-induced TCMK-1 cells. The silence of METTL14 lowered the cell viability, the levels of MDA, Fe²⁺ and lipid peroxidation in the LPS-stimulated AKI model in vitro and in vivo, but increase GSH levels. Moreover, the up-regulation of ferroptosis-related proteins by LPS was notably inhibited by the knockdown of METTL14. In addition, silencing METTL14 reduced the m6A and mRNA levels of LPCAT3. Furthermore, the efficacy of METTL14 downregulation on the ferroptosis in the LPS-induced TCMK-1 cells were antagonized by LPCAT3 overexpression. Taken together, our findings revealed that METTL14 knockdown resisted ferroptosis in sepsis-induced AKI through lessening the level of LPCAT3 mediated by m6A modification.

01 Dec 2025·Nano-Micro Letters

High Fe-Loading Single-Atom Catalyst Boosts ROS Production by Density Effect for Efficient Antibacterial Therapy

Article

Author: Yan, Qixin ; Mao, Lijie ; Chen, Si ; Lu, Xiangyu ; Shi, Jianlin ; Huang, Fang ; Lin, Han ; Zhang, Zhimin

AbstractThe current single-atom catalysts (SACs) for medicine still suffer from the limited active site density. Here, we develop a synthetic method capable of increasing both the metal loading and mass-specific activity of SACs by exchanging zinc with iron. The constructed iron SACs (h3-FNC) with a high metal loading of 6.27 wt% and an optimized adjacent Fe distance of ~ 4 Å exhibit excellent oxidase-like catalytic performance without significant activity decay after being stored for six months and promising antibacterial effects. Attractively, a “density effect” has been found at a high-enough metal doping amount, at which individual active sites become close enough to interact with each other and alter the electronic structure, resulting in significantly boosted intrinsic activity of single-atomic iron sites in h3-FNCs by 2.3 times compared to low- and medium-loading SACs. Consequently, the overall catalytic activity of h3-FNC is highly improved, with mass activity and metal mass-specific activity that are, respectively, 66 and 315 times higher than those of commercial Pt/C. In addition, h3-FNCs demonstrate efficiently enhanced capability in catalyzing oxygen reduction into superoxide anion (O2·−) and glutathione (GSH) depletion. Both in vitro and in vivo assays demonstrate the superior antibacterial efficacy of h3-FNCs in promoting wound healing. This work presents an intriguing activity-enhancement effect in catalysts and exhibits impressive therapeutic efficacy in combating bacterial infections.

01 Aug 2025·Neural Regeneration Research

Hypidone hydrochloride (YL-0919) ameliorates functional deficits after traumatic brain injury in mice by activating the sigma-1 receptor for antioxidation

Article

Author: Hou, Xiaojuan ; Yang, Yixin ; Bai, Yafan ; Zhang, Yue ; Li, Jinfeng ; Wang, Guyan ; Li, Yunfeng ; Ma, Hui

JOURNAL/nrgr/04.03/01300535-202508000-00023/figure1/v/2024-09-30T120553Z/r/image-tiff Traumatic brain injury involves complex pathophysiological mechanisms, among which oxidative stress significantly contributes to the occurrence of secondary injury. In this study, we evaluated hypidone hydrochloride (YL-0919), a self-developed antidepressant with selective sigma-1 receptor agonist properties, and its associated mechanisms and targets in traumatic brain injury. Behavioral experiments to assess functional deficits were followed by assessment of neuronal damage through histological analyses and examination of blood-brain barrier permeability and brain edema. Next, we investigated the antioxidative effects of YL-0919 by assessing the levels of traditional markers of oxidative stress in vivo in mice and in vitro in HT22 cells. Finally, the targeted action of YL-0919 was verified by employing a sigma-1 receptor antagonist (BD-1047). Our findings demonstrated that YL-0919 markedly improved deficits in motor function and spatial cognition on day 3 post traumatic brain injury, while also decreasing neuronal mortality and reversing blood–brain barrier disruption and brain edema. Furthermore, YL-0919 effectively combated oxidative stress both in vivo and in vitro. The protective effects of YL-0919 were partially inhibited by BD-1047. These results indicated that YL-0919 relieved impairments in motor and spatial cognition by restraining oxidative stress, a neuroprotective effect that was partially reversed by the sigma-1 receptor antagonist BD-1047. YL-0919 may have potential as a new treatment for traumatic brain injury.

100 Deals associated with Glutathione

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00014	-	V03AB32	DB00143

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Drug intoxication	Japan	Choseido Pharmaceutical Co., Ltd.	22 Aug 1967
Heavy Metal Poisoning	Japan	Choseido Pharmaceutical Co., Ltd.	22 Aug 1967
Hypertension, Pregnancy-Induced	Japan	Choseido Pharmaceutical Co., Ltd.	22 Aug 1967
Vomiting of pregnancy	Japan	Choseido Pharmaceutical Co., Ltd.	22 Aug 1967
Chorioretinitis	Japan	Choseido Pharmaceutical Co., Ltd.	30 Jun 1967
Corneal Ulcer	Japan	Choseido Pharmaceutical Co., Ltd.	30 Jun 1967
Hyperpigmentation	Japan	Choseido Pharmaceutical Co., Ltd.	30 Jun 1967
Keratitis	Japan	Choseido Pharmaceutical Co., Ltd.	30 Jun 1967
Leukopenia	Japan	Choseido Pharmaceutical Co., Ltd.	30 Jun 1967
Stomatitis	Japan	Choseido Pharmaceutical Co., Ltd.	30 Jun 1967
Liver Diseases	China	-	-
Toxicity due to chemotherapy	China	-	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02251041 (CAPITL, CTgov)	Phase 2	Reperfusion Injury	143	C1-Inhibitor+Epoprostenol+Infliximab+Melatonin+Alfa-tocopherol+Human recombinant erythropoietin+Glutathione	giqrrlolxk(zrgktlfjsc) = mhdaxrfgzb iefvezimuu (eclprilyiy, iymxkgjsiy - takeavgyps) View more	-	23 Aug 2024
ARVO2016	Not Applicable	Aphakia	-	glutathione (Grx1-roGFP2)	czrelfyxbz(mmdqldwshw) = pzxpwputsk vkqhbbxmgi (xmaftdppdb )	-	01 May 2016
The MiniZID study (IAS2014)	Not Applicable	HIV Infections	142	Standard dose (600 mg) of zidovudine	(epxwuoqowh) = lmsoyfoidr vrbktkryuf (mdqyebxzbr )	Positive	01 Jan 2014
The MiniZID study (IAS2014)	Not Applicable	HIV Infections	142	Reduced dose (400 mg) of zidovudine	(epxwuoqowh) = xpwgfzwkjq vrbktkryuf (mdqyebxzbr )	Positive	01 Jan 2014
NCT01450267 (ERS2012)	Phase 3	Cystic Fibrosis First line	94	Inhaled Glutathione	zarzrnbcqt(obkhfvofnl) = ylngzusfdy cqkpzltupe (qntjcckcse )	Positive	01 Sep 2012
NCT01450267 (ERS2012)	Phase 3	Cystic Fibrosis First line	94	Placebo	zarzrnbcqt(obkhfvofnl) = gxeicwuyhp cqkpzltupe (qntjcckcse )	Positive	01 Sep 2012
ARVO2005	Not Applicable	stress oxidative	-	Glutathione (Inner retinal layers)	jvpoecsjtv(rnyaauzbiz) = yrwvxgmgkv qmdymnwoji (fnouxszlnm )	-	01 May 2005